Tradition Wealth Management’s ImmunityBio IBRX Stock Holding History

Tradition Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200	Closed	-$3K	–	1184
2021 Q2	$3K	Buy	+200	New	+$3.3K	﹤0.01%	1136

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Tradition Wealth Management's IBRX Position: Q3 2021 in Review

Tradition Wealth Management sold out of ImmunityBio (IBRX) in Q3 2021, closing a stake of 200 shares — an estimated $3K sold.

Tradition Wealth Management first reported a position in IBRX in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2021.

Tradition Wealth Management reported no remaining ImmunityBio position as of Q3 2021 after selling out during the quarter.
Tradition Wealth Management sold 200 ImmunityBio shares in Q3 2021, an estimated $3K.
Tradition Wealth Management first reported a position in ImmunityBio in Q2 2021 and held it in 1 quarter.
Tradition Wealth Management's ImmunityBio position peaked at $3K in Q2 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2021.

Based on Tradition Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.